Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study.

Staaf J, Glodzik D, Bosch A, Vallon-Christersson J, Reuterswärd C, Häkkinen J, Degasperi A, Amarante TD, Saal LH, Hegardt C, Stobart H, Ehinger A, Larsson C, Rydén L, Loman N, Malmberg M, Kvist A, Ehrencrona H, Davies HR, Borg Å, Nik-Zainal S.

Nat Med. 2019 Oct;25(10):1526-1533. doi: 10.1038/s41591-019-0582-4. Epub 2019 Sep 30.

2.

Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series.

Vallon-Christersson J, Häkkinen J, Hegardt C, Saal LH, Larsson C, Ehinger A, Lindman H, Olofsson H, Sjöblom T, Wärnberg F, Ryden L, Loman N, Malmberg M, Borg Å, Staaf J.

Sci Rep. 2019 Aug 21;9(1):12184. doi: 10.1038/s41598-019-48570-x.

3.

Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.

Lundgren C, Bendahl PO, Borg Å, Ehinger A, Hegardt C, Larsson C, Loman N, Malmberg M, Olofsson H, Saal LH, Sjöblom T, Lindman H, Klintman M, Häkkinen J, Vallon-Christersson J, Fernö M, Rydén L, Ekholm M.

Breast Cancer Res Treat. 2019 Nov;178(2):459-467. doi: 10.1007/s10549-019-05378-7. Epub 2019 Aug 20.

4.

Prediction of Lymph Node Metastasis in Breast Cancer by Gene Expression and Clinicopathological Models: Development and Validation within a Population-Based Cohort.

Dihge L, Vallon-Christersson J, Hegardt C, Saal LH, Häkkinen J, Larsson C, Ehinger A, Loman N, Malmberg M, Bendahl PO, Borg Å, Staaf J, Rydén L.

Clin Cancer Res. 2019 Nov 1;25(21):6368-6381. doi: 10.1158/1078-0432.CCR-19-0075. Epub 2019 Jul 24.

PMID:
31340938
5.

Refinement of breast cancer molecular classification by miRNA expression profiles.

Søkilde R, Persson H, Ehinger A, Pirona AC, Fernö M, Hegardt C, Larsson C, Loman N, Malmberg M, Rydén L, Saal L, Borg Å, Vallon-Christerson J, Rovira C.

BMC Genomics. 2019 Jun 17;20(1):503. doi: 10.1186/s12864-019-5887-7.

6.

The Molecular Basis for Inhibition of Stemlike Cancer Cells by Salinomycin.

Huang X, Borgström B, Stegmayr J, Abassi Y, Kruszyk M, Leffler H, Persson L, Albinsson S, Massoumi R, Scheblykin IG, Hegardt C, Oredsson S, Strand D.

ACS Cent Sci. 2018 Jun 27;4(6):760-767. doi: 10.1021/acscentsci.8b00257. Epub 2018 Jun 14.

7.

Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative.

Rydén L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, Lindman H, Ehinger A, Saal LH, Borg Å.

Br J Surg. 2018 Jan;105(2):e158-e168. doi: 10.1002/bjs.10741.

8.

Structure-Activity Relationships in Salinomycin: Cytotoxicity and Phenotype Selectivity of Semi-synthetic Derivatives.

Borgström B, Huang X, Hegardt C, Oredsson S, Strand D.

Chemistry. 2017 Feb 10;23(9):2077-2083. doi: 10.1002/chem.201603621. Epub 2016 Nov 17.

PMID:
27740704
9.

Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.

Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, Törngren T, Vallon-Christersson J, Hegardt C, Häkkinen J, Jönsson G, Grabau D, Malmberg M, Kristoffersson U, Rehn M, Gruvberger-Saal SK, Larsson C, Borg Å, Loman N, Saal LH.

Ann Oncol. 2016 Aug;27(8):1532-8. doi: 10.1093/annonc/mdw209. Epub 2016 May 18.

10.

Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.

Huang X, Borgström B, Kempengren S, Persson L, Hegardt C, Strand D, Oredsson S.

BMC Cancer. 2016 Feb 23;16:145. doi: 10.1186/s12885-016-2142-3.

11.

Stem cell biomarker ALDH1A1 in breast cancer shows an association with prognosis and clinicopathological variables that is highly cut-off dependent.

Sjöström M, Hartman L, Honeth G, Grabau D, Malmström P, Hegardt C, Fernö M, Niméus E.

J Clin Pathol. 2015 Dec;68(12):1012-9. doi: 10.1136/jclinpath-2015-203092. Epub 2015 Jul 14.

PMID:
26175266
12.

The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine.

Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, Brueffer C, Tang MH, Reuterswärd C, Schulz R, Karlsson A, Ehinger A, Malina J, Manjer J, Malmberg M, Larsson C, Rydén L, Loman N, Borg Å.

Genome Med. 2015 Feb 2;7(1):20. doi: 10.1186/s13073-015-0131-9. eCollection 2015.

13.

Semisynthesis of SY-1 for investigation of breast cancer stem cell selectivity of C-ring-modified salinomycin analogues.

Huang X, Borgström B, Månsson L, Persson L, Oredsson S, Hegardt C, Strand D.

ACS Chem Biol. 2014 Jul 18;9(7):1587-94. doi: 10.1021/cb5002153. Epub 2014 May 29.

PMID:
24841425
14.

Synthetic modification of salinomycin: selective O-acylation and biological evaluation.

Borgström B, Huang X, Pošta M, Hegardt C, Oredsson S, Strand D.

Chem Commun (Camb). 2013 Nov 4;49(85):9944-6. doi: 10.1039/c3cc45983g.

PMID:
24037337
15.

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes.

Holm K, Grabau D, Lövgren K, Aradottir S, Gruvberger-Saal S, Howlin J, Saal LH, Ethier SP, Bendahl PO, Stål O, Malmström P, Fernö M, Rydén L, Hegardt C, Borg Å, Ringnér M.

Mol Oncol. 2012 Oct;6(5):494-506. doi: 10.1016/j.molonc.2012.06.002. Epub 2012 Jun 20.

16.

The retinoblastoma gene undergoes rearrangements in BRCA1-deficient basal-like breast cancer.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Gruvberger-Saal SK, Saal LH, Holm K, Hegardt C, Arason A, Fagerholm R, Persson C, Grabau D, Johnsson E, Lövgren K, Magnusson L, Heikkilä P, Agnarsson BA, Johannsson OT, Malmström P, Fernö M, Olsson H, Loman N, Nevanlinna H, Barkardottir RB, Borg Å.

Cancer Res. 2012 Aug 15;72(16):4028-36. Epub 2012 Jun 15.

17.

Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.

Holm K, Staaf J, Jönsson G, Vallon-Christersson J, Gunnarsson H, Arason A, Magnusson L, Barkardottir RB, Hegardt C, Ringnér M, Borg A.

Breast Cancer Res Treat. 2012 Jun;133(2):583-94. doi: 10.1007/s10549-011-1817-3. Epub 2011 Oct 16.

PMID:
22002566
18.

CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.

Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, Fernö M, Grabau D, Borg A, Hegardt C.

BMC Cancer. 2011 Sep 29;11:418. doi: 10.1186/1471-2407-11-418.

19.

The antiproliferative effect of dietary fiber phenolic compounds ferulic acid and p-coumaric acid on the cell cycle of Caco-2 cells.

Janicke B, Hegardt C, Krogh M, Onning G, Akesson B, Cirenajwis HM, Oredsson SM.

Nutr Cancer. 2011;63(4):611-22. doi: 10.1080/01635581.2011.538486.

PMID:
21500097
20.

Reduction of the putative CD44+CD24- breast cancer stem cell population by targeting the polyamine metabolic pathway with PG11047.

Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM.

Anticancer Drugs. 2010 Nov;21(10):897-906. doi: 10.1097/CAD.0b013e32833f2f77.

PMID:
20838207
21.

Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics.

Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, Hegardt C, Gunnarsson H, Fagerholm R, Strand C, Agnarsson BA, Kilpivaara O, Luts L, Heikkilä P, Aittomäki K, Blomqvist C, Loman N, Malmström P, Olsson H, Johannsson OT, Arason A, Nevanlinna H, Barkardottir RB, Borg A.

Breast Cancer Res. 2010;12(3):R42. doi: 10.1186/bcr2596. Epub 2010 Jun 24.

22.

Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.

Holm K, Hegardt C, Staaf J, Vallon-Christersson J, Jönsson G, Olsson H, Borg A, Ringnér M.

Breast Cancer Res. 2010;12(3):R36. doi: 10.1186/bcr2590. Epub 2010 Jun 18.

23.

Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

J Clin Oncol. 2010 Apr 10;28(11):1813-20. doi: 10.1200/JCO.2009.22.8775. Epub 2010 Mar 15.

PMID:
20231686
24.

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.

Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.

Breast Cancer Res Treat. 2010 Jul;122(2):315-24. doi: 10.1007/s10549-009-0568-x. Epub 2009 Oct 1.

PMID:
19795205
25.

Effect of polyamine deficiency on proteins involved in Okazaki fragment maturation.

Johansson VM, Miniotis MF, Hegardt C, Jönsson G, Staaf J, Berntsson PS, Oredsson SM, Alm K.

Cell Biol Int. 2008 Dec;32(12):1467-77. doi: 10.1016/j.cellbi.2008.08.018. Epub 2008 Aug 22.

PMID:
18786645
26.

Molecular mechanisms underlying N1, N11-diethylnorspermine-induced apoptosis in a human breast cancer cell line.

Holst CM, Staaf J, Jönsson G, Hegardt C, Oredsson SM.

Anticancer Drugs. 2008 Oct;19(9):871-83. doi: 10.1097/CAD.0b013e32830f902b.

PMID:
18766001
27.

The CD44+/CD24- phenotype is enriched in basal-like breast tumors.

Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.

Breast Cancer Res. 2008;10(3):R53. doi: 10.1186/bcr2108. Epub 2008 Jun 17.

28.

Different cell cycle kinetic effects of N1,N11-diethylnorspermine-induced polyamine depletion in four human breast cancer cell lines.

Myhre L, Alm K, Hegardt C, Staaf J, Jönsson G, Larsson S, Oredsson SM.

Anticancer Drugs. 2008 Apr;19(4):359-68. doi: 10.1097/CAD.0b013e3282f7f518.

PMID:
18454046
29.

Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma.

Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, Peterson C, Malmström P, Isola J, Borg A, Fernö M.

Clin Cancer Res. 2007 Apr 1;13(7):1987-94.

30.

Induction of apoptotic cell death by putrescine.

Takao K, Rickhag M, Hegardt C, Oredsson S, Persson L.

Int J Biochem Cell Biol. 2006;38(4):621-8. Epub 2005 Dec 1.

PMID:
16406751
31.

Intratumor versus intertumor heterogeneity in gene expression profiles of soft-tissue sarcomas.

Francis P, Fernebro J, Edén P, Laurell A, Rydholm A, Domanski HA, Breslin T, Hegardt C, Borg A, Nilbert M.

Genes Chromosomes Cancer. 2005 Jul;43(3):302-8.

PMID:
15834945
32.

Spermine prevents cytochrome c release in glucocorticoid-induced apoptosis in mouse thymocytes.

Hegardt C, Andersson G, Oredsson SM.

Cell Biol Int. 2003;27(2):115-21.

PMID:
12662968
33.
34.

Different roles of spermine in glucocorticoid- and Fas-induced apoptosis.

Hegardt C, Andersson G, Oredsson SM.

Exp Cell Res. 2001 Jun 10;266(2):333-41.

PMID:
11399061
35.

Changes in polyamine metabolism during glucocorticoid-induced programmed cell death in mouse thymus.

Hegardt C, Andersson G, Oredsson SM.

Cell Biol Int. 2000;24(12):871-80.

PMID:
11114236
36.

[Cooperation is A and O for field hospitals].

Hegardt C.

Lakartidningen. 1993 Jun 9;90(23):2209. Swedish. No abstract available.

PMID:
8502080
37.

[Field hospital--for whom?].

Hegardt C.

Lakartidningen. 1993 May 26;90(21):2027-8. Swedish. No abstract available.

PMID:
8502044
38.

[Letter: Save us from travelling surgeons].

Hegardt C.

Lakartidningen. 1975 Aug 13;72(33):3052-3. Swedish. No abstract available.

PMID:
1165671

Supplemental Content

Loading ...
Support Center